Drug
IM-101
Drug Profile
| Therapeutic Class | Immunotherapy |
| Drug Class | Therapeutic Vaccines |
| Group | Therapeutic Vaccines |
| Mechanism of Action | Cell-based vaccine |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Data on this page refer exclusively to patients treated with
IM-101 combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Therapeutic Vaccines group page.